US EditionGuinea-Bissau suspends Trump-backed hepatitis B vaccine study for ethical review
Guinea-Bissau halted a $1.6 million U.S.-funded hepatitis B vaccine trial due to ethical concerns and lack of technical resources, pending a national review.
- Guinea-Bissau is suspending a Trump administration-backed hepatitis B vaccine study on newborns, pending an ethical review.
- The study is designed as a randomized controlled trial, with some infants given the hepatitis B vaccine at birth and others not.
- Some experts have suggested that the research plan is unethical, because it will withhold vaccines that work from newborns at significant risk of infection.
45 Articles
45 Articles
This is still the biggest blur that surrounds a highly controversial clinical trial in Guinea-Bissau. Conducted by a Danish team and funded by the United States, the study focuses on 14,000 newborns: half of them receive a hepatitis B vaccine from birth, and the other has to wait six weeks. A practice that is highly critical in a country where nearly 20% of the population is carrying the virus.
Guinea-Bissau suspends a US-funded vaccine trial as African scientists question its motives
Officials from the US Department of Health and Human Services, which funded the controversial study, say that it will proceed as planned. Officials from the US Department of Health and Human Services, which funded the controversial study, say that it will proceed as planned.
DNyuz
GH HeadlinesKennedy Plan to Test a Vaccine in West African Babies Is Blocked
The West African nation of Guinea-Bissau has suspended a controversial U.S.-funded study of the hepatitis B vaccine in infants there after an outcry from public health researchers over the ethics of the work. The Centers for Disease Control and Prevention approved a $1.6 million grant for the study last month, days after the health secretary, Robert F. Kennedy Jr., lifted the agency’s longstanding recommendation to give the vaccine to all infant…
MedPage Today
Anti-Aging, Acupuncture and Health NewsGuinea-Bissau Suspends Trump-Backed Hep B Vaccine Trial for Ethical Review
(MedPage Today) -- Guinea-Bissau is suspending a Trump administration-backed hepatitis B vaccine study on newborns in the West African country, pending an ethical review, the health minister said Thursday. A six-person ethics committee didn't...
Associated Press News
Guinea-Bissau suspends Trump-backed hepatitis B vaccine study for ethical review
Guinea-Bissau's health minister says the government is suspending a Trump administration-backed hepatitis B vaccine study on newborns in the West African country pending an ethical review.
Coverage Details
Bias Distribution
- 69% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
